Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
72
SARTF Quote, Financials, Valuation and Earnings
Last price:
$220.00
Seasonality move
:
16.06%
Day range:
$220.00 - $220.00
52-week range:
$165.00 - $243.35
Dividend yield:
0.36%
P/E ratio:
102.22x
P/S ratio:
3.91x
P/B ratio:
4.84x
Volume:
--
Avg. volume:
4
1-year change:
20.03%
Market cap:
$15.2B
Revenue:
$3.7B
EPS (TTM):
$2.15
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SARTF
Sartorius AG
|
-- | -- | -- | -- | -- |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.85% | -86.85% | $137.43 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -14.98% | $11.24 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.89% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SARTF
Sartorius AG
|
$220.00 | -- | $15.2B | 102.22x | $0.79 | 0.36% | 3.91x |
|
BNTX
BioNTech SE
|
$96.25 | $137.43 | $23.1B | 191.55x | $0.00 | 0% | 6.55x |
|
CVAC
CureVac NV
|
$5.12 | $5.31 | $1.2B | 7.16x | $0.00 | 0% | 14.22x |
|
IFRX
InflaRx NV
|
$1.06 | $11.24 | $71.8M | -- | $0.00 | 0% | 327.52x |
|
IMTX
Immatics NV
|
$10.18 | $18.75 | $1.2B | 42.21x | $0.00 | 0% | 13.60x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SARTF
Sartorius AG
|
61.54% | 0.974 | 36.14% | 0.37x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SARTF
Sartorius AG
|
$459.5M | $172.6M | 2.49% | 5.43% | 17.52% | -$76.6M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Sartorius AG vs. Competitors
-
Which has Higher Returns SARTF or BNTX?
BioNTech SE has a net margin of 7.35% compared to Sartorius AG's net margin of -1.89%. Sartorius AG's return on equity of 5.43% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital SARTFSartorius AG46.63% $0.74 $9.5B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About SARTF or BNTX?
Sartorius AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $137.43 which suggests that it could grow by 43.04%. Given that BioNTech SE has higher upside potential than Sartorius AG, analysts believe BioNTech SE is more attractive than Sartorius AG.
Company Buy Ratings Hold Ratings Sell Ratings SARTFSartorius AG0 0 0 BNTXBioNTech SE14 5 0 -
Is SARTF or BNTX More Risky?
Sartorius AG has a beta of 0.979, which suggesting that the stock is 2.141% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock SARTF or BNTX?
Sartorius AG has a quarterly dividend of $0.79 per share corresponding to a yield of 0.36%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius AG pays 60.77% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Sartorius AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SARTF or BNTX?
Sartorius AG quarterly revenues are $985.3M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Sartorius AG's net income of $72.5M is higher than BioNTech SE's net income of -$33.5M. Notably, Sartorius AG's price-to-earnings ratio is 102.22x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius AG is 3.91x versus 6.55x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SARTFSartorius AG3.91x 102.22x $985.3M $72.5M BNTXBioNTech SE6.55x 191.55x $1.8B -$33.5M
-
Which has Higher Returns SARTF or CVAC?
CureVac NV has a net margin of 7.35% compared to Sartorius AG's net margin of -5832.47%. Sartorius AG's return on equity of 5.43% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital SARTFSartorius AG46.63% $0.74 $9.5B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About SARTF or CVAC?
Sartorius AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 3.97%. Given that CureVac NV has higher upside potential than Sartorius AG, analysts believe CureVac NV is more attractive than Sartorius AG.
Company Buy Ratings Hold Ratings Sell Ratings SARTFSartorius AG0 0 0 CVACCureVac NV1 3 0 -
Is SARTF or CVAC More Risky?
Sartorius AG has a beta of 0.979, which suggesting that the stock is 2.141% less volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock SARTF or CVAC?
Sartorius AG has a quarterly dividend of $0.79 per share corresponding to a yield of 0.36%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius AG pays 60.77% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Sartorius AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SARTF or CVAC?
Sartorius AG quarterly revenues are $985.3M, which are larger than CureVac NV quarterly revenues of $63.3M. Sartorius AG's net income of $72.5M is lower than CureVac NV's net income of $319.3M. Notably, Sartorius AG's price-to-earnings ratio is 102.22x while CureVac NV's PE ratio is 7.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius AG is 3.91x versus 14.22x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SARTFSartorius AG3.91x 102.22x $985.3M $72.5M CVACCureVac NV14.22x 7.16x $63.3M $319.3M
-
Which has Higher Returns SARTF or IFRX?
InflaRx NV has a net margin of 7.35% compared to Sartorius AG's net margin of -51538.49%. Sartorius AG's return on equity of 5.43% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital SARTFSartorius AG46.63% $0.74 $9.5B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About SARTF or IFRX?
Sartorius AG has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 960.74%. Given that InflaRx NV has higher upside potential than Sartorius AG, analysts believe InflaRx NV is more attractive than Sartorius AG.
Company Buy Ratings Hold Ratings Sell Ratings SARTFSartorius AG0 0 0 IFRXInflaRx NV5 2 0 -
Is SARTF or IFRX More Risky?
Sartorius AG has a beta of 0.979, which suggesting that the stock is 2.141% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock SARTF or IFRX?
Sartorius AG has a quarterly dividend of $0.79 per share corresponding to a yield of 0.36%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius AG pays 60.77% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Sartorius AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SARTF or IFRX?
Sartorius AG quarterly revenues are $985.3M, which are larger than InflaRx NV quarterly revenues of $27.8K. Sartorius AG's net income of $72.5M is higher than InflaRx NV's net income of -$14.3M. Notably, Sartorius AG's price-to-earnings ratio is 102.22x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius AG is 3.91x versus 327.52x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SARTFSartorius AG3.91x 102.22x $985.3M $72.5M IFRXInflaRx NV327.52x -- $27.8K -$14.3M
-
Which has Higher Returns SARTF or IMTX?
Immatics NV has a net margin of 7.35% compared to Sartorius AG's net margin of -974.45%. Sartorius AG's return on equity of 5.43% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital SARTFSartorius AG46.63% $0.74 $9.5B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About SARTF or IMTX?
Sartorius AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 84.19%. Given that Immatics NV has higher upside potential than Sartorius AG, analysts believe Immatics NV is more attractive than Sartorius AG.
Company Buy Ratings Hold Ratings Sell Ratings SARTFSartorius AG0 0 0 IMTXImmatics NV9 0 0 -
Is SARTF or IMTX More Risky?
Sartorius AG has a beta of 0.979, which suggesting that the stock is 2.141% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock SARTF or IMTX?
Sartorius AG has a quarterly dividend of $0.79 per share corresponding to a yield of 0.36%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius AG pays 60.77% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Sartorius AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SARTF or IMTX?
Sartorius AG quarterly revenues are $985.3M, which are larger than Immatics NV quarterly revenues of $6.1M. Sartorius AG's net income of $72.5M is higher than Immatics NV's net income of -$59.1M. Notably, Sartorius AG's price-to-earnings ratio is 102.22x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius AG is 3.91x versus 13.60x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SARTFSartorius AG3.91x 102.22x $985.3M $72.5M IMTXImmatics NV13.60x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.19% over the past day.
